Holen Sie sich die Stockscreener-App
117.56
0.84%
-0.99
Handel nachbörslich:
117.55
-0.01
-0.01%
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - AD HOC NEWS
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - Stock Titan
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - Stock Titan
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics (MNPR) acting CMO plans 1-share sale - Stock Titan
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar appoints medical affairs head, presents at liver meeting By Investing.com - Investing.com South Africa
Monopar appoints medical affairs head, presents at liver meeting - Investing.com
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLDThe Liver Meeting® 2026 - The Manila Times
Monopar (MNPR) Price Update: Rises 1.94% to $118.75 at the Close; Price Context: the $112.81 to $124.69 Range Remains in Focus in the Latest ReadingLate Stage Breakouts - vinanet.vn
Monopar (MNPR) Close in Focus: Ends Up by 0.70% at $117.30 for the Current Session; Technical Position - vinanet.vn
Monopar: Licensing Agreement, Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’ - Seeking Alpha
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
Cantor downgrades Monopar stock on valuation after 90% rally By Investing.com - Investing.com Canada
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile - TipRanks
Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A - Stock Titan
Monopar Therapeutics stock price target raised to $133 by BTIG - Investing.com Canada
MNPR Maintained by BTIG -- Price Target Raised to $133 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Adage Capital discloses 4.76% Monopar Therapeutics (MNPR) stake including warrants - Stock Titan
Form 8K Monopar Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Monopar Therapeutics' Q2 Net Loss Widens - marketscreener.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update on ALXN1840 NDA Submission - Quiver Quantitative
Monopar Reports Q2 2026 Net Loss of $5.3 Million - Quiver Quantitative
Monopar Therapeutics reports Q2 2026: $5.3M net loss, $134.3M cash on hand - TradingView
Monopar Therapeutics 2Q 2026: Net income $(5.31M), EPS $(0.62) — 10-Q Summary - TradingView
Monopar Therapeutics (MNPR) deepens R&D spend but retains $134M cash runway - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Monopar Therapeutics Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR - MarketBeat
Why is Monopar Therapeutics stock up today? Resistance levels in focus - tradersunion.com
Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year HighWhat's Next? - marketbeat.com
MNPR Q2'26 Earnings: EPS estimate is (0.66) USD - TradingView
Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains - Traders Union
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):